Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abbott Laboratories (ABT – Research Report) ...

Linda brings more than 20 years of financial, operational and executive leadership success at innovative life science companies,” said Matt Patterson, Chairman of Remix Therapeutics Board of Directors ...

Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in a deal worth over $1 ...

Arvinas reported phase 1 results with ARV-471 last December which backed the drug's mechanism of action and provided encouraging early results on safety and efficacy, including a reduction in ...

Healthcare & Pharmaceuticalscategory· March 11, 2025 Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results Pfizer and Arvinas' experimental treatment failed to delay ...

At close: April 8 at 4:00:02 PM EDT ...

You’ve viewed 1 of 5 articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.